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ABSTRACT
Objective Hepatitis C virus (HCV) infection is associated 
with an increased risk of cardiovascular disease (CVD) and 
reduced health- related quality of life (HRQoL). Although 
physical activity (PA)/exercise has been shown to reduce 
CVD risk and improve HRQoL in patients with liver 
disease, there is limited data in HCV. We aimed to explore 
the association between PA/exercise levels, CVD risk 
and HRQoL in patients with HCV and assess individuals’ 
attitudes to PA/exercise.
Design Cross- sectional observational study recruiting 
consecutive patients with HCV from viral hepatitis clinics. 
Data were collected on CVD risk factors, anthropometry, 
HRQoL and the Exercise Benefits and Barriers Scale 
(EBBS).
Results 86 patients were recruited (71% men, 94% 
white, age 52±13 years); 49% of the cohort self- reported 
to be currently active. Although HRQoL was reduced 
across the cohort, patients that were regularly ‘active’ 
reported significantly higher HRQoL scores across 
Short- Form 36v2 domains compared with their inactive 
counterparts (p<0.05). Metabolic and cardiovascular 
characteristics were no different between groups stratified 
by PA/exercise status (p>0.05). EBBS scores were similar 
in the ‘active’ versus ‘inactive’ groups, however, patients 
categorised as ‘active’ scored significantly higher on the 
psychological outlook and social interaction subscales 
(p<0.05) than those that were ‘inactive’. There were 
significant associations between EBBS scores and HRQoL 
(p<0.05).
Conclusions PA/exercise is associated with increased 
HRQoL in patients with HCV irrespective of clinical 
parameters. Addressing specific motivators/barriers to 
exercise for patients will be key to designing effective PA/
exercise interventions in this patient population to ensure 
maximum uptake and adherence.
INTRODUCTION
Hepatitis C virus (HCV) infection is a major 
cause of chronic liver disease affecting an 
estimated 71 million people worldwide.1 
The disease causes numerous extrahepatic 
manifestations resulting in a high burden 
of comorbidity, including increased risk of 
cardiovascular disease (CVD)2–7 and neuro-
psychiatric disorders and depression8–10 even 
after successful antiviral treatment. Health- 
related quality of life (HRQoL) is also signifi-
cantly reduced compared with non- HCV 
infected individuals.11 12
Recently, we developed a holistic care 
bundle to identify and target modifiable clin-
ical parameters and health behaviours in indi-
viduals with HCV in order to improve overall 
health status and clinical prognosis.7 A central 
component of this work was the assessment 
of exercise participation levels, which showed 
that fewer individuals with HCV meet current 
physical activity (PA) recommendations than 
the general population.13 We also showed 
Summary box
What is already known about this subject?
 ► Individuals with hepatitis C virus (HCV) have an in-
creased risk of cardiovascular disease and reduced 
health- related quality of life (HRQoL) compared with 
the general population.
What are the new findings?
 ► Individuals with HCV who engage in regular mod-
erate or vigorous physical activity (PA) have sig-
nificantly better HRQoL compared with inactive 
individuals.
 ► Active individuals have higher scores for psycholog-
ical outlook and social interaction subscales of the 
Exercise Benefits and Barriers Scale.
 ► There were significant associations between atti-
tude to exercise and HRQoL in individuals with HCV.
How might it impact on clinical practice in the 
foreseeable future?
 ► Exercise/PA could be an important tool for improving 
HRQoL in patients with HCV.
 ► Addressing specific motivators and barriers to ex-
ercise will be key in designing effective exercise 














astroenterol: first published as 10.1136/bm





2 Hallsworth K, et al. BMJ Open Gastro 2021;8:e000591. doi:10.1136/bmjgast-2020-000591
Open access 
that sedentary behaviour was associated with reduced 
HRQoL.
Although others have previously shown PA/exercise 
to improve HRQoL in patients with liver disease,14–16 few 
studies have assessed the strength of this association in 
patients with HCV, or explored individual’s attitudes to 
PA/exercise. This information is fundamental for devel-
oping effective strategies for engaging individuals with 
HCV identified as sedentary in lifestyle improvement 
programmes. Therefore, we aimed to explore the associa-
tion between sedentary behaviour and HRQoL and assess 
individuals’ attitudes to PA/exercise using the Exercise 
Benefits and Barriers Scale (EBBS). Our specific aims 
were to: (1) determine whether individuals with HCV 
who engage in regular PA/exercise have fewer cardiomet-
abolic risk factors than sedentary individuals; (2) define 
the perceived benefits and barriers to PA/exercise in 
this cohort; (3) determine whether there is a relation-




This cross- sectional, observational study recruited consec-
utive patients with HCV (treated or untreated) attending 
the viral hepatitis clinics at The Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Newcastle upon Tyne, 
UK. This was a substudy of the previously reported 
ENHANCE study7 and included 86 patients (out of 100) 
who had complete EBBS data. Unfortunately, 14 of the 
patients did not complete the EBBS survey or did not 
complete is fully so were excluded from the analysis. 
Their clinical and demographic data was similar to the 
main cohort.
Patients
Individuals aged 18 years or older were included if they 
had chronic HCV infection (defined as HCV RNA detect-
able in blood for >6 months) or had achieved sustained 
virological response (SVR=cure of infection) 3 months 
after antiviral treatment. Exclusions were: currently on 
antiviral treatment for HCV or within 3 months post- 
treatment; coinfection with hepatitis B or HIV; history of 
hepatocellular carcinoma; liver transplantation; decom-
pensated cirrhosis (Child- Pugh Score ≥7); or were unable 
to give informed consent.
Clinical and laboratory data
All clinical and laboratory data were collected at the time 
of enrolment including age, gender, ethnicity, weight, 
waist circumference, waist to hip ratio and body mass 
index. Body composition was measured using 8- point 
Bioelectrical Impendence Analysis (SECA BIA mBCA 525 
Machine, SECA, UK). Blood tests were taken including: 
full blood count, liver enzymes, HbA1c, lipids, glucose, 
vitamin D, thyroid stimulating hormone and HCV RNA, 
which were analysed in an accredited NHS clinical labo-
ratory. A detailed medical history, including a list of 
current prescribed medications, was recorded and cross- 
referenced with information from primary care. Details 
about each individual’s history of HCV infection was 
also collected including: suspected route of infection, 
previous antiviral treatment and outcomes, and current 
status (active HCV viraemia or SVR). Stage of liver fibrosis 
was assessed using transient elastography and cirrhosis 
was defined as a liver stiffness measurement >12.5 kPa, 
liver biopsy demonstrating cirrhosis or imaging evidence 
of cirrhosis with portal hypertension.
Details of any history of CVD including ischaemic heart 
disease, cerebrovascular disease, peripheral vascular 
disease or atrial fibrillation were recorded. We used the 
QRISK3 ( www. qrisk. org) to determine an individual’s 
estimated risk of a major cardiovascular event in the 
next 10 years. Smoking history was documented as never 
smoked, current smoker or previous smoker (for >1 year). 
The metabolic syndrome and its individual features were 
defined according to the International Diabetes Feder-
ation criteria.17 Information on past or current history 
of mental health disorders was also collected. A history 
of ‘significant’ mental health disorder was defined as 
one where pharmacological treatment was used for its 
treatment.
HRQoL was determined using the Hepatitis Quality 
of Life Questionnaire (HQLQv2), a survey constructed 
to assess the functional health and well- being of patients 
with HCV, using the Short- Form 36v2 (SF36v2) Health 
Survey and 15 additional hepatitis- specific questions rele-
vant in assessing the impact of hepatitis.18 SF36v2 scores 
presented in this study were normalised to the US general 
population to have a mean of 50 and SD of 10.19 There-
fore, SF36v2 scores below 50 were considered reduced 
HRQoL in this study. Scores were normalised to US data 
because this is more recent than UK data, by 12 years 
and there has been a marked change in HRQoL over 
that time. US and UK populations have similar HRQoL. 
For the hepatitis specific scores, the Hepatitis Distress 
scale (HD), Positive Wellbeing (PWB), Hepatitis Specific 
Limitations scale (HLIM) and Hepatitis Specific Health 
Distress scale (HHD), scores ranged from 0 to 100 (not 
normalised to the US population) with higher scores 
indicating better HRQoL.
Details about each patients’ current self- reported PA/
exercise levels were recorded as sedentary, engaging in 
regular moderate PA/exercise (≥150 min/week of activity 
that leads to faster breathing, increased heart rate and 
feeling warmer (eg, walking 3–4 m/hour and household 
tasks, like mowing the lawn or vacuuming)) or regular 
vigorous PA/exercise (≥75 min/week of activity that 
leads to very hard breathing, shortness of breath, rapid 
heartbeat and should leave a person unable to main-
tain a conversation comfortably (eg, running at 6–8 m/
hour or cycling 12–14 m/hour)). Patients completed the 
EBBS which provides a measurement of the perceived 
benefits and barriers to participating in PA/exercise, 
and has been demonstrated to be a valid tool in a range 
of clinical cohorts in adults with chronic diseases.20 The 
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EBBS contains 43 statements pertaining to ‘ideas about 
exercise’ and is scored on a Likert- scale with responses 
ranging from 4 (strongly agree) to 1 (strongly disagree). 
Twenty- nine statements relate to perceived benefits of 
exercise and 14 relate to perceived barriers. Scores for 
the total instrument range from 43 to 172 with higher 
scores representing a more positive attitude towards PA/
exercise.
A measure of socioeconomic status/deprivation was 
assessed by mapping the home postcode for each patient 
onto the English Indices of Deprivation using the Index 
of Multiple Deprivation (IMD).21 The lower layer super 
output area (LSOA) was calculated for each individual 
patient postcode. The LSOA with a rank of 1 is the most 
deprived and the LSOA with a rank of 32 844 is the least 
deprived. Deciles for the IMD are calculated by ranking 
the 32 844 LSOAS in England into 10 equal groups (1 
being the most deprived area decile and 10 the least 
deprived).
Statistical analysis
Descriptive information for each variable was derived 
and the distribution assessed to determine normality. 
Metric and normally distributed variables are reported 
as mean±SD, non- normally distributed variables are 
reported as median and IQR, and categorical variables 
are reported as frequency (percentage) unless otherwise 
stated. The cohort was stratified according to activity 
level (‘inactive’ vs engaging in moderate or vigorous PA/
exercise (termed ‘active’)), with differences between 
dichotomised variables assessed using independent 
t- tests, Mann- Whitney U tests or Fisher’s exact tests. 
Differences between EBBS scores were assessed using a 
general linear model with multiple comparisons adjusted 
using Bonferroni correction. Multiple linear regression 
models were used to investigate the associations between 
clinical characteristics and EBBS scores. Models were fit 
to estimate associations with sequential adjustment for 
age, gender and participation in exercise. Data analysis 
was performed with SPSS (IBM SPSS Statistics V.25, IBM 
Corp) with statistical significance inferred at a two- tailed 




A total of 86 patients (42 active and 44 inactive) were 
included in the analysis. The clinical characteristics of 
all patients are presented in tables 1 and 2. The gender, 
ethnicity and socioeconomic status distributions were 
similar between active and inactive patients (table 1; 
p>0.05). Metabolic and cardiovascular characteristics, 
as well as blood biochemistry, were also similar between 
patient groups stratified by PA/exercise status (table 2). 
The prevalence of a psychological comorbidity was high 
Table 1 Patients demographic and anthropometric characteristics
All patients
Exercise status
Inactive Active P value
Demographic characteristics
  n 86 44 42 –
  Age (years) 52±13 51±14 53±11 0.432*
  Male (%) 71 68 71 0.639†
  White (%) 94 93 95 0.998 †
  IMDR 10 239±8869 9429±8256 11 087±9495 0.391*
  IMDD 3 (4) 3 (4) 3 (5) 0.789†
  Current or previous IDU (%) 70 68 53 0.025†
  Current or previous heavy alcohol intake (%) 44 42 46 0.687†
Anthropometry
  Weight (kg) 82.56±19.73 84.42±21.34 80.65±17.99 0.381*
  BMI (kg/m2) 27.69±6.02 28.45±6.42 26.90±5.56 0.240*
  Waist circumference (cm) 95.30±15.03 96.40±14.78 94.10±15.40 0.494*
  Hip circumference (cm) 101.69±13.34 103.81±15.22 99.57±10.94 0.173*
  Waist- to- hip ratio 0.93 (0.1) 0.92 (0.1) 0.95 (0.1) 0.483‡
  Fat mass (%) 29.06±10.20 28.39±11.85 29.73±8.40 0.634*
Metric and normally distributed variables are reported as mean±SD; non- normally distributed variables are reported as median and IQR, and 
categorical variables are reported as frequency (percentage).
*independent t- test.
†Fisher’s exact test.
‡Mann- Whitney U test.
BMI, body mass index; IDU, injecting drug use; IMDD, Index of Multiple Deprivation Decile; IMDR, Index of Multiple Deprivation Rank.
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in both groups and greatest in those characterised as 
inactive (inactive: 57% vs active 41%, p=0.031).
Self-reported exercise participation and EBBS scores
Self- reported exercise participation and EBBS scores are 
presented in table 3. From our sample of 86 patients, 49% 
(n=42) of the cohort self- reported to be currently active, 
of which 14% (n=12) self- reported regular participation 
in vigorous PA/exercise. Of those patients classified with 
cirrhosis (n=30, (35%)), 43% (n=13) were physically 
active, compared with 52% (n=29) of those classified 
as non- cirrhotic. Of those patients with active viraemia 
(28%, (n=24)), 50% were classified as physically active; 
Table 2 Metabolic and cardiovascular characteristics, and blood biochemistry
All patients
Exercise status
Inactive Active P value
Metabolic and cardiovascular characteristics
Cirrhosis (%) 35 39 30 0.602*
Sustained virological response (%) 72 71 71 0.998*
SBP (mm Hg) 134±19 130±21 137±17 0.104†
DBP (mm Hg) 83 (13) 78 (11) 86 (15) 0.496‡
Hypertensive (%) 62 55 66 0.180*
Metabolic syndrome (%) 27 30 25 0.620*
Metabolic syndrome features 2 (2) 2 (2) 2 (2) 0.359*
Dyslipidaemia (%) 17 16 18 0.376*
Diabetes (%) 15 16 14 1.000*
CVD (%) 9 11 7 0.713*
CKD (%) 2 5 0 0.494*
Depression (%) 50 57 41 0.281*
Smoking (%) 48 55 39 0.226*
QRISK3 11.69±11.32 11.57±12.62 11.82±9.97 0.922†
Biological age (years) 60±13 59±14 62±12 0.255†
Blood biochemistry
Platelets (109/L) 229.68±94.48 225.07±87.08 234.40±102.35 0.652†
White cell count (109/L) 7.55±2.41 7.63±2.81 7.48±1.94 0.771†
Albumin (g/L) 45.92±3.23 44.93±3.01 46.95±3.15 0.004†§
Bilirubin (μmol/L) 7.50 (6.25) 7.00 (7.00) 8.00 (6.00) 0.388‡
ALP (μL/L) 82.26±27.11 86.77±31.11 77.54±21.55 0.119†
ALT (U/L) 28.00 (28.25) 28.00 (33.00) 28.00 (19.00) 0.417‡
GGT (U/L) 40.00 (61.00) 45.00 (100.00) 33.00 (53.00) 0.619‡
AST (U/L) 27.00 (19.75) 26.50 (27.00) 27.50 (17.35) 0.588‡
HbA1c (mmol/mol) 38.00 (6.00) 38.50 (6.00) 38.00 (5.50) 0.493‡
Vitamin D (nmol/L) 45.00 (42.50) 37.00 (32.50) 53.00 (36.50) 0.580‡
Total cholesterol (mmol/L) 4.42±1.12 4.19±1.18 4.65±1.01 0.549†
Triglycerides (mmol/L) 1.40 (0.95) 1.69 (1.17) 1.30 (1.00) 0.611‡
HDL (mmol/L) 1.40 (0.50) 1.40 (0.53) 1.30 (0.55) 0.837‡
Cholesterol/HDL ratio (mmol/L) 3.20 (1.49) 2.95 (1.25) 3.50 (1.41) 0.604‡
LDL (mmol/L) 3.07±1.08 2.85±1.13 3.30±1.00 0.062†
TSH (mU/L) 1.74 (1.16) 1.75 (1.19) 1.74 (0.41) 0.410‡
**Between group difference at p<0.01; ***between group difference at p<0.001.
Metric and normally distributed variables are reported as mean±SD; non- normally distributed variables are reported as median and IQR, and 
categorical variables are reported as frequency (percentage).
*Fisher’s exact test.
†Independent t- test.
‡Mann- Whitney U test.
§Between group difference at p<0.05.
ALP, Alkaline Phosphatase; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; CKD, Chronic Kidney Disease; CVD, cardiovascular 
disease; DBP, Diastolic Blood Pressure; GGT, Gamma Glutamyl Transferase; HDL, High Density Lipoprotein; LDL, Low Density Lipoprotein; SBP, 
Systolic Blood Pressure; TSH, thyroid stimulating hormone.
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Table 3 Self- report Exercise Benefit and Barrier Scale (EBBS) scores
All patients
Exercise status
Inactive Active P value
Total EBBS score 122.69±16.46 117.66±15.91 127.95±15.52 0.416*
Combined benefit items score 83.24±13.67 79.61±14.96 87.05±11.13 0.189*
Combined barrier items score 39.44±6.34 38.05±6.06 40.90±6.37 0.744*
Perceived benefit items
  Life enhancement subscale
25: My disposition is improved by exercise 2.85±0.66 2.77±0.77 2.93±0.51 0.253*
26: Exercising helps me sleep better at night 2.85±0.69 2.75±0.78 2.95±0.58 0.110*
29: Exercise helps me decrease fatigue 2.62±0.72 2.50±0.79 2.74±0.63 0.290*
32: Exercise improves my self- concept 2.92±0.65 2.77±0.68 3.07±0.60 0.175*
34: Exercising increases my mental alertness 2.90±0.69 2.77±0.74 2.02±0.60 0.302*
35: Exercise allows me to carry out normal activities without 
becoming tired
2.81±0.64 2.73±0.62 2.90±0.66 0.649*
36: Exercise improves the quality of my work 2.71±0.63 2.64±0.69 2.79±0.56 0.137*
41: Exercise improves overall body function 2.93±0.66 2.86±0.70 3.00±0.62 0.315*
Standardised subscale score 2.82±0.51 2.72±0.55 2.93±0.44 0.653*
  Physical performance subscale
7: Exercise increases my muscle strength 3.08±0.72 2.98±0.73 3.19±0.71 0.262*
15: Exercises increases my level of physical fitness 3.12±0.71 3.05±0.71 3.19±0.71 0.696*
17: My muscle tone is improved with exercise 3.06±0.64 2.89±0.69 3.24±0.53 0.035* †
18: Exercising improves functioning of my cardiovascular 
system
3.06±0.62 2.86±0.67 3.26±0.50 0.020* †
22: Exercise increases my stamina 3.14±0.65 3.02±0.73 3.26±0.54 0.330*
23: Exercise improves my flexibility 3.09±0.71 3.02±0.79 3.17±0.62 0.449*
31: My physical endurance is improved by exercise 3.03±0.66 2.91±0.68 3.17±0.62 0.214*
43: Exercise improves the way my body looks 2.99±0.68 2.93±0.76 3.05±0.58 0.452*
Standardised subscale score 3.07±0.52 2.96±0.57 3.19±0.45 0.795*
  Psychological outlook subscale
1: I enjoy exercise 2.80±0.78 2.50±0.85 3.12±0.55 0.001* ‡
2: Exercise decreases feelings of stress and tension for me 2.85±0.78 2.66±0.83 3.03±0.70 0.136*
3: Exercise improves my mental health 2.77±0.75 2.57±0.76 2.98±0.68 0.018* †
8: Exercise gives me a sense of personal accomplishment 2.90±0.85 2.73±0.90 3.07±0.78 0.257*
10: Exercising makes me feel relaxed 2.83±0.69 2.66±0.78 3.00±0.54 0.095*
20: I have improved feelings of well- being from exercise 2.93±0.73 2.80±0.79 3.07±0.64 0.283*
Standardised subscale score 2.84±0.62 2.65±0.69 3.05±0.46 0.024* †
  Social interaction subscale
11: Exercising lets me have contact with friends and persons 
I enjoy
2.49±0.72 2.30±0.73 2.69±0.64 0.032* †
30: Exercising is a good way for me to meet new people 2.70±0.63 2.61±0.65 2.79±0.61 0.200*
38: Exercise is good entertainment for me 2.76±0.77 2.68±0.83 2.83±0.70 0.539*
39: Exercise increases my acceptance by others 2.40±0.74 2.39±0.84 2.40±0.63 0.252*
Standardised subscale score 2.58±0.52 2.49±0.54 2.68±0.49 0.017* †
  Preventive health subscale
5: I prevent heart attacks by exercising 2.93±0.70 2.82±0.72 3.05±0.66 0.505*
13: Exercising increases my levels of physical fitness 2.91±0.57 2.77±0.60 3.05±0.49 0.148*
27: I will live longer if I exercise 2.85±0.69 2.68±0.77 3.02±0.56 0.114*
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of those patients without active viraemia (72% (n=62)), 
51% were classified as physically active.
Across the whole cohort, the highest scoring exer-
cise benefit subscale was physical performance, and the 
social interaction subscale was scored lowest (tables 3 
and 4). Preventive health, psychological outlook and life 
enhancement subscales were largely comparable (tables 3 
and 4). Physical performance was negatively associated 
with social interaction (r=−0.251; p=0.020). The highest 
scoring individual benefit item was ‘exercise improves 
my flexibility’ and the lowest was ‘exercise increases my 
acceptance by others’. Family discouragement and time 
expenditure were rated similarly as the main overarching 
barriers to exercise (tables 3 and 4), with patients scoring 
‘exercise takes too much time from family relationships’ 
as the highest individual barrier item. The lowest scoring 
barrier subscale was physical exertion, with patients 
scoring ‘exercise tires me out’ as the lowest individual 
barrier item. Overall, the perceived benefits (mean±SD: 
2.87±0.47) and barriers (mean±SD: 2.82±0.45) to exer-
cise were equally weighted (p=0.386) in a 1:1 ratio. Mean 
scores for all benefits and barriers were between 2 and 3, 
which, equated to between ‘agree’ and ‘disagree’ on the 
EBBS scoring scale. Stratification by PA/exercise status 
did not reveal statistically significant between- group 
differences in overall EBBS scores, however, patients 
categorised as active scored significantly higher on the 
psychological outlook and social interaction subscales 
(table 3). Specifically, active patients scored ‘Exercise 
improves my mental health’ and ‘Exercise lets me have 
contact with friends and persons I enjoy’ significantly 
greater than inactive patients (table 3).
Relationship between HRQoL and PA
HRQoL was reduced with mean scores for all SF36v2 
domains below that of the general population (data shown 
All patients
Exercise status
Inactive Active P value
  Exercise milieu subscale
9: Places for me to exercise are too far away 3.00±0.75 2.91±0.77 3.10±0.73 0.124*
12: I am too embarrassed to exercise 2.99±0.75 2.84±0.86 3.14±0.65 0.215*
14: It costs too much to exercise 2.98±0.74 2.91±0.83 2.05±0.62 0.411*
16: Exercise facilities do not have convenient schedules for 
me
2.87±0.72 2.84±0.71 2.90±0.73 0.821*
28: I think people in exercise clothes look funny 2.97±0.76 2.86±0.77 3.07±0.75 0.643*
42: There are too few places for me to exercise 2.77±0.78 2.61±0.81 2.93±0.71 0.160*
Standardised subscale score 2.93±0.52 2.83±0.50 3.03±0.53 0.319*
  Time expenditure subscale
4: Exercising takes too much of my time 2.86±0.74 2.77±0.80 2.95±0.66 0.226*
24: Exercise takes too much time from family relationships 3.15±0.62 3.09±0.60 3.21±0.65 0.253*
37: Exercise takes too much time from my family 
responsibilities
3.10±0.63 3.00±0.65 3.21±0.61 0.179*
Standardised subscale score 3.04±0.52 2.95±0.54 3.13±0.49 0.447*
  Physical exertion subscale
6: Exercise tires me out 2.09±0.71 1.98±0.66 2.21±0.75 0.465*
19: I am fatigued by exercise 2.35±0.75 2.30±0.82 2.40±0.66 0.371*
40: Exercise is hard work for me 2.28±0.82 2.18±0.90 2.38±0.73 0.149*
Standardised subscale score 2.24±0.61 2.15±0.64 2.33±0.56 0.248*
  Family discouragement subscale
21: My spouse (or significant other) does not encourage 
exercising
3.03±0.80 2.91±0.80 3.17±0.79 0.491*
33: My family members do not encourage me to exercise 3.00±0.80 2.84±0.86 3.17±0.70 0.214*
Standardised subscale score 3.02±0.69 2.88±0.67 3.17±0.69 0.059*
***Between group difference at p<0.001.




†Between group difference at p<0.05.
‡Between group difference at p<0.01.
§Independent t- test.
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previously7). However, patients categorised as active 
demonstrated significantly higher HRQoL scores (signi-
fying better HRQoL) across SF36v2 domains, including: 
Physical Functioning (41±11 vs 48±11, p=0.031), General 
Health (37±11 vs 45±11, p=0.001), Vitality (39±10 vs 
48±12, p<0.001), Social Functioning (35±14 vs 46±13, 
p=0.003), Mental Health (37±14 vs 48±11, p=0.003), Phys-
ical Component Score (41±12 vs 47±10, p=0.003), Mental 
Component Score (36±15 vs 46±33, p=0.003), Hepatitis 
Distress (42±33 vs 65±33, p=0.005), Physical Wellbeing 
(40±28 vs 64±23, p=0.017), for inactive versus active indi-
viduals, respectively.
Relationship between EBBS scores and HRQoL
Table 5 shows results from linear regression analyses 
between EBBS scores with self- report HRQoL. Significant 
associations were observed between total EBBS score, 
combined benefit item score and combined barrier 
item score with Physical Component Score and Mental 
Component Score, as well as all HCV specific compo-
nents (table 5). Associations remained robust following 
adjustment for confounders and further adjustment 
for activity status (table 5). Further, significant associa-
tions were observed between Life Enhancement, Phys-
ical Performance, Psychological Outlook, Preventative 
Health and Exercise Milieu EBBS subscales with Physical 
Component Score (p<0.05), and, Preventative Health, 
Exercise Milieu, and Physical Exertion EBBS subscales 
with Mental Component Score (p<0.05); these associ-
ations remained significant following adjustment for 
confounders and activity status.
DISCUSSION
Our findings show that patients with a history of HCV 
infection (treated or untreated) who regularly undertake 
PA/exercise report significantly higher HRQoL scores 
compared with their inactive counterparts, irrespective 
of CVD risk and comorbidity. Collectively, these findings 
suggest that PA/exercise should be promoted as a poten-
tial therapeutic tool to improve HRQoL in patients with 
HCV, even if participation may not result in improved 
cardiometabolic and biochemical parameters.
The clinical picture of HCV and recovery from treat-
ment is characterised by a highly comorbid state coupled 
with reduced life expectancy. We have previously shown a 
high prevalence of cardiometabolic risk in this cohort of 
patients with HCV,7 however, the finding that increased 
cardiometabolic risk is ubiquitous within this patient 
group irrespective of PA/exercise participation was 
somewhat unexpected. Participation in regular PA/exer-
cise is widely recognised to reduce cardiometabolic risks 
in both the general population and those with chronic 
disease.22–24 Our observational data would suggest that 
PA/exercise participation may have little impact on 
cardiometabolic characteristics in HCV, although in a 
relatively small sample size. However, it is worth noting 
that within our ‘active’ HCV cohort, rates of statin and 
antihypertensive prescribing were low (14% and 32%, 
respectively), and smoking rates were very high (39% 
current smokers vs 14% in the UK general population25), 
which collectively, may have negated the potential bene-
fits of regular PA/exercise participation on cardiometa-
bolic parameters. It is important to note however, that we 
investigated the associations between clinical parameters 
and self- reported PA/exercise participation at a single 
time point, and therefore longitudinal and interven-
tional studies are required to fully establish whether PA/
exercise has a therapeutic role in modifying cardiomet-
abolic risk in this patient group. It is widely accepted 
that PA/exercise is an important and effective therapy 
for improving the pathology and symptoms related to 
specific liver diseases26–32 with studies demonstrating 
that moderate PA is beneficial in maintaining func-
tional capacity, improving body composition, glucose 
homoeostasis, dyslipidaemia and hypertension,33 34 as 
well as reducing hepatic steatosis and improving liver 
Table 4 Standardised perceived benefit and barrier subscale multiple comparison matrix
1 2 3 4 5
Perceived benefit items
  1: Life enhancement – <0.001*** 0.984 <0.001*** 0.994
  2: Physical performance – <0.001*** <0.001*** <0.001***
  3: Psychological outlook – 0.002*** 0.957
  4: Social interaction – <0.001***
  5: Preventive health –
Perceived barrier items
  1: Exercise milieu – 0.952 <0.001*** 0.957
  2: Time expenditure – <0.001*** 0.996
  3: Physical exertion – <0.001***
  4: Family discouragement –
*Between item difference at p<0.05; **between item difference at p<0.01; ***between item difference at p<0.001; post- hoc comparisons 
adjusted using Bonferroni corrections.
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function.35 36 Although such benefits are often assumed 
to apply to individuals with HCV, there is little available 
empirical evidence to support this. In addition, although 
it was beyond the scope of the present analysis, it would 
be of interest to assess the mediating impact of viraemic 
status as well as other prevalent clinical characteristics on 
PA levels given that recent data demonstrates that HCV 
increases fatigue37 and that fatigue is improved following 
SVR.38
Our data support previous research highlighting patients 
with HCV have a significantly reduced HRQoL.7 11 12 The 
present study extends this work, showing that patients with 
HCV who are regularly active report significantly higher 
HRQoL, across SF36v2 domains, compared with inactive 
counterparts. The main motivator for exercising was to 
improve physical performance, with those that exercised 
regularly indicating that improving muscle tone, stamina 
and cardiovascular fitness as being most important. 
This supports a rationale for practitioners to encourage 
patients with HCV to undertake regular PA/exercise as 
a way to improve HRQoL beyond simply targeting liver 
health. Furthermore, we show that individuals with HCV 
who were active report higher scores on the EBBS indi-
cating a more positive perception towards PA/exercise, 
with psychological outlook and social interaction scoring 
significantly higher in those active compared with non- 
active HCV individuals. This is important given that a 
significant proportion of patients with HCV present with 
mental health disorders and would suggest that PA/exer-
cise participation may be an effective tool to specifically 
address this within this cohort.
Overall, patients with HCV placed equal weighting 
on the perceived benefits and barriers to exercise. It is 
therefore important to acknowledge that this ‘equipoise’ 
may be unlikely to lead to behaviour change within the 
setting of current clinical practice, which focuses on 
simply promoting PA/exercise. It is therefore important 
for healthcare professionals (HCPs) to communicate to 
patients that the benefits of PA/exercise, extend beyond 
liver- health. Indeed, linking exercise participation to 
tangible improvements in HRQoL may be perceived as 
more important for patients with HCV than linking exer-
cise participation to routine clinical biomarkers. Given 
that the benefits of PA/exercise need to be perceived as of 
high enough importance for patients to want to overcome 
the barriers of changing PA/exercise behaviours, HCPs 
also need to assess barriers in this population to enable 
the development of successful lifestyle interventions.
Table 5 Linear regression analysis between EBBS scores with self- report hepatitis quality of life scores
Model 1 Model 2 Model 3
β (95% CI) P value β (95% CI) P value β (95% CI) P value
Total EBBS score
PCS 0.242 (0.097 to 0.387) 0.001** 0.255 (0.113 to 0.396) 0.001** 0.213 (0.067 to 0.359) 0.005**
MCS 0.295 (0.111 to 0.480) 0.002** 0.287 (0.102 to 0.471) 0.003** 0.216 (0.029 to 0.403) 0.024*
HD 0.892 (0.468 to 1.316) <0.001*** 0.884 (0.466 to 1.303) <0.001*** 0.747 (0.321 to 1.173) 0.001**
PWB 0.633 (0.282 to 0.984) 0.001** 0.615 (0.264 to 0.967) 0.001** 0.446 (0.099 to 0.794) 0.012**
HLIM 0.783 (0.438 to 1.128) <0.001*** 0.793 (0.444 to 1.142) <0.001*** 0.737 (0.372 to 1.102) <0.001***
HHD 0.422 (−0.006 to 0.849) 0.053 0.406 (−0.084 to 1.044) 0.094 0.358 (−0.099 to 0.806) 0.116
Combined benefit item score
PCS 0.220 (0.041 to 0.399) 0.016* 0.222 (0.047 to 0.398) 0.013* 0.171 (−0.007 to 0.348) 0.059
MCS 0.233 (0.004 to 0.463) 0.046* 0.232 (0.004 to 0.460) 0.046* 0.147 (−0.079 to 0.374) 0.200
HD 0.762 (0.231 to 1.294) 0.005** 0.458 (−0.110 to 1.026) 0.112 0.605 (0.083 to 1.127) 0.024*
PWB 0.635 (0.202 to 1.067) 0.005** 0.629 (0.198 to 1.060) 0.111 0.429 (0.009 to 0.849) 0.046*
HLIM 0.811 (0.383 to 1.239) <0.001*** 0.813 (0.380 to 1.246) <0.001*** 0.735 (0.286 to 1.183) 0.002**
HHD 0.234 (−0.303 to 0.771) 0.338 0.253 (−0.281 to 0.787) 0.349 0.172 (−0.374 to 0.732) 0.521
Combined barrier item score
PCS 0.601 (0.223 to 0.979) 0.002** 0.678 (0.310 to 1.045) <0.001*** 0.594 (0.226 to 0.961) 0.002**
MCS 0.898 (0.429 to 1.366) <0.001*** 0.853 (0.379 to 1.326) 0.001** 0.721 (0.254 to 1.187) 0.003**
HD 2.363 (1.276 to 3.448) <0.001*** 2.274 (1.188 to 3.360) <0.001*** 1.998 (0.929 to 3.068) <0.001***
PWB 1.423 (0.452 to 2.394) 0.005** 1.331 (0.345 to 2.317) 0.009** 1.017 (0.087 to 1.948) 0.033*
HLIM 1.631 (0.653 to 2.608) 0.001** 1.703 (0.706 to 2.700) 0.001** 1.554 (0.551 to 2.556) 0.003**
HHD 1.772 (0.716 to 2.829) 0.001** 1.641 (0.562 to 2.721) 0.003** 1.562 (0.446 to 2.678) 0.007**
Models were fit to estimate associations with sequential adjustment for age and gender (model 2), and exercise status (model 3).
*Significant association at p<0.05; **significant association at p<0.01; ***significance association at p<0.001.
HD, Hepatitis Distress; HHD, Hepatitis- specific Health Distress; HLIM, Hepatitis- specific Limitations; MCS, Mental Health Component; PCS, 
Physical Health Component; PWB, Positive Wellbeing.
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The greatest barriers to exercise were time, with 
patients in both groups indicating that taking time away 
from family for PA/exercise was prohibitive, and that 
family members discouraged PA/exercise. Both of these 
barriers need to be addressed to design a successful PA/
exercise intervention for this patient population and 
thus future research should seek to establish the atti-
tudes of family members early in the design stage. In the 
present study, other commonly perceived barriers such 
as cost and accessibility to PA/exercise were perceived no 
differently in those that did and did not exercise regu-
larly. Although this is somewhat of a surprising finding, 
it is likely attributable to a lack of difference in socioeco-
nomic status between the two groups with patients in this 
study.
Study limitations
The main limitations to the study are firstly the use 
of self- reporting to ascertain PA levels at a single time 
point, which lacks the precision of objective methods 
and may result in over- reporting or under- reporting of 
PA/exercise duration and intensity and may also not 
reflect historic activity levels. Future studies should 
seek to employ objective measures of PA (such as 
accelerometry) to provide a detailed description of 
24- hour activity levels (including intensity) over a 7- day 
period. Second, the EBBS asks patients to ‘score’ their 
attitudes towards exercise on a scale of 1–4 but does 
not allow patients to elaborate on their responses. A 
more in- depth qualitative analysis of patient (and their 
families/friends) perceptions of benefits and barriers 
to exercise participation may be warranted prior to 
designing a targeted intervention for patients with 
HCV. Third, we were unable to ascertain whether the 
association between PA/exercise and reduced HRQoL 
was ‘cause’ or ‘effect’. Fourth, the sample size was rela-
tively small and consisted of predominately relatively 
older white men who were seen in secondary care 
which may limit generalisability and may be a factor 
accounting for our findings showing no association 
between PA/activity and cardiometabolic risk. Further 
larger studies in more diverse cohorts should be under-
taking to confirm or refute these findings.
In conclusion, PA/exercise could be an important tool 
for improving HRQoL in patients with HCV irrespec-
tive of improvements in clinical parameters. Addressing 
specific motivators/barriers to exercise for patients will 
be key to designing effective PA/exercise interventions in 
this patient population to ensure maximum uptake and 
adherence.
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